Voluntary nationwide recall: Clonazepam (Endo – November)

Dec. 2024Pharmacy Updates

Endo USA Inc. has recalled certain lots of Clonazepam Orally Disintegrating Tablets, USP (C-IV). This is an expansion of a previous recall by Endo. Clonazepam is used to treat panic disorder and certain seizures.

This product is being recalled because the cartons of some packs show the incorrect product strength. The blister strips inside the product pack show the correct strength.

Using this drug at a higher dose than prescribed may cause sleepiness, dizziness, loss of muscle control, and confusion.

To see if your medication was recalled, please contact your doctor or the pharmacy where you received it or visit the FDA website below. If you have an affected lot of Clonazepam, you should stop using the medicine and return it to the place where you got it or throw it away.

As of Nov. 18, there had been no reports of adverse events related to this recall.

To learn more about this recall:

  • Call Inmar Inc. at 1-855-589-1869. Help is available Monday through Friday from 9 a.m. to 5 p.m. EST.
  • Visit the FDA website.

Recent Announcements

Important announcement – Telehealth submissions

As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.
Sep. 2025Important Notices

October 2025 UPMC for You and UPMC Community HealthChoices Formulary Update

Effective October 1st, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to non-participation in the Medicaid Drug Rebate Program.
Sep. 2025Pharmacy Updates

Biosimilar Medication Formulary Updates

Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab products
Sep. 2025Pharmacy Updates